Andrés Muñoz

1.1k total citations
18 papers, 228 citations indexed

About

Andrés Muñoz is a scholar working on Oncology, Hepatology and Surgery. According to data from OpenAlex, Andrés Muñoz has authored 18 papers receiving a total of 228 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 4 papers in Hepatology and 3 papers in Surgery. Recurrent topics in Andrés Muñoz's work include Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Andrés Muñoz is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Andrés Muñoz collaborates with scholars based in Spain, United States and Australia. Andrés Muñoz's co-authors include David A. Katerndahl, Josep‐María Ribera, Antonio Salar, Eva González‐Barca, Alicia Bailén, Maite Encuentra, Alberto Fernández de Sevilla, Eva Domingo‐Doménech, Javier Briones and José Gómez‐Codina and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Andrés Muñoz

17 papers receiving 220 citations

Peers

Andrés Muñoz

ONCOL

PFM

SURGE

EPIDE

Keigo Chida Japan

Venkata K. Pokuri United States

Gianluca Businello Italy

Estelle Cauchin France

Virginia Mancini Italy

Emilie Lemasle France

Najib Ben Khaled Germany

Masaichi Ogawa Japan

Waleed Sabry Canada

Maria Teresa Vietri Italy

Keigo Chida Japan

Andrés Muñoz

138 ×0.8

ONCOL

57 ×0.8

PFM

52 ×1.0

SURGE

22 ×0.8

EPIDE

30 ×1.2

Citations per year, relative to Andrés Muñoz Andrés Muñoz (= 1×) peers Keigo Chida

Countries citing papers authored by Andrés Muñoz

Since Specialization

Citations

This map shows the geographic impact of Andrés Muñoz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrés Muñoz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrés Muñoz more than expected).

Fields of papers citing papers by Andrés Muñoz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrés Muñoz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrés Muñoz. The network helps show where Andrés Muñoz may publish in the future.

Co-authorship network of co-authors of Andrés Muñoz

This figure shows the co-authorship network connecting the top 25 collaborators of Andrés Muñoz. A scholar is included among the top collaborators of Andrés Muñoz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrés Muñoz. Andrés Muñoz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Muñoz, Andrés, et al.. (2025). Technology-Supported Distance Learning of Writing in a Low-Interactivity, Low-Literacy Context: Lessons Learned. Language Teaching Research Quarterly. 47. 93–112.

Molpeceres, C., Rocío Ramos‐Medina, Andrés Márquez, et al.. (2023). Laser transfer for circulating tumor cell isolation in liquid biopsy. International Journal of Bioprinting. 9(4). 720–720. 5 indexed citations

García‐Alfonso, Pilar, Eduardo Díaz‐Rubio, Albert Abad, et al.. (2021). First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. Drugs & Aging. 38(3). 219–231. 4 indexed citations

González‐Barca, Eva, Francisco Capote, José Gómez‐Codina, et al.. (2020). Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. Annals of Hematology. 100(4). 1023–1029. 8 indexed citations

Rivera, Fernando, F. P. Antia, Teresa Macarulla, et al.. (2019). PCN470 EXPERT CONSENSUS ON PATIENT-REPORTED OUTCOMES FOR THE MANAGEMENT OF PANCREATIC CANCER. Value in Health. 22. S528–S528. 1 indexed citations

García‐Alfonso, Pilar, et al.. (2019). FOLFOXIRI plus biologics in advanced colorectal cancer. Expert Opinion on Biological Therapy. 19(5). 411–422. 6 indexed citations

Macarulla, Teresa, Alfredo Carrato, Rienzi Díaz‐Navarro, et al.. (2018). Management and supportive treatment of frail patients with metastatic pancreatic cancer. Journal of Geriatric Oncology. 10(3). 398–404. 6 indexed citations

Álvarez, Rafael, Alfredo Carrato, Jorge Adeva, et al.. (2018). Management of hyperbilirubinaemia in pancreatic cancer patients. European Journal of Cancer. 94. 26–36. 8 indexed citations

Gracián, Antonio Cubillo, Andrew Dean, Andrés Muñoz, et al.. (2017). YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD). Annals of Oncology. 28. v211–v211. 22 indexed citations

10.

Hidalgo, Manuel, Roberto Pazo-Cid, Carmen Guillén‐Ponce, et al.. (2017). A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC). Annals of Oncology. 28. v212–v212. 7 indexed citations

11.

García‐Alfonso, Pilar, Manuel Chaves-Conde, Andrés Muñoz, et al.. (2015). Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer. 15(1). 327–327. 10 indexed citations

12.

Alfonso, Pilar, Manuel Chaves-Conde, Andrés Muñoz, et al.. (2013). Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology. 31(4_suppl). 501–501. 1 indexed citations

13.

Alfonso, Pilar, Manuel Chaves-Conde, Andrés Muñoz, et al.. (2012). P-0256 Phase II Study to Evaluate Efficacy and Safety of Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer (MCRC) Patients. Annals of Oncology. 23. iv103–iv104. 1 indexed citations

14.

García‐Alfonso, Pilar, et al.. (2011). Safety and efficacy of first-line XELIRI with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies.. Journal of Clinical Oncology. 29(4_suppl). 560–560. 1 indexed citations

15.

Muñoz, Andrés, Carles Pericay, Vicente Alonso, et al.. (2010). Phase II study of bevacizumab (B) plus oxaliplatin (Ox) plus capecitabine (C) followed by bevacizumab (B) plus erlotinib (E) as first-line treatment in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 28(15_suppl). 3539–3539. 2 indexed citations

16.

González‐Barca, Eva, Eva Domingo‐Doménech, José Gómez‐Codina, et al.. (2007). Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica. 92(11). 1489–1494. 99 indexed citations

17.

Muñoz, Andrés & David A. Katerndahl. (1998). Diagnosis and Management of Acute Pancreatitis. Journal of the American Academy of Nurse Practitioners. 10(10). 478–482. 46 indexed citations

18.

Valbuena, José R., et al.. (1990). Carcinoma del Ano Experiencia con 82 Pacientes. SHILAP Revista de lepidopterología. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact